Trimming the Fat: Supreme Court Slims Down Skinny Label Liability

On June 4, 2026, the United States Supreme Court issued its decision in Hikma Pharmaceuticals USA Inc. v. Amarin Pharma, Inc. In its decision, the Supreme Court reversed the Federal Circuit, and held that Amarin’s complaint failed to plausibly allege that Hikma’s skinny label generic induced infringement of Amarin’s patents under 35 U.S.C. §271(b)….
By: Arnall Golden Gregory LLP